Soliqua FAQ

No, Soliqua 100/33 should not be used to treat type 1 diabetes. Soliqua 100/33 has not been studied nor approved by the Food and Drug Administration to treat that condition. It’s only approved to treat type 2 diabetes.

Yes, Soliqua 100/33 contains insulin. Soliqua 100/33 is made of two drugs, one of which is insulin glargine, a long-acting insulin. The second drug is lixisenatide, which is a glucagon-like peptide 1 (GLP-1) receptor agonist.

If you miss a dose of Soliqua 100/33, skip that dose and continue with your next scheduled dose. Do not try to catch up by taking an extra dose or increasing the next dose. This can cause dangerous side effects.

If Soliqua 100/33 is effective and safe for you, you’ll probably use this drug long term. Soliqua 100/33 is typically used long term to treat type 2 diabetes. Soliqua 100/33 can cause mild or serious side effects. The following list contains some of the key side effects that may occur while taking Soliqua 100/33. This list doesn’t include all possible side effects. For more information on the possible side effects of Soliqua 100/33, or tips on how to deal with a troubling side effect, talk with your doctor or pharmacist. You can also refer to this in-depth article about potential side effects of Soliqua 100/33.

Soliqua 100/33 begins to work right after you inject it. However, it reaches its highest effect about 2.5 to 3 hours after each injection. Study data is limited for use of Soliqua 100/33 during pregnancy in humans. However, animal studies show that there may be a risk of congenital anomalies (also known as birth defects) with the use of lixisenatide during pregnancy. Lixisenatide is one of the drugs found in Soliqua 100/33. Therefore, Soliqua 100/33 should only be used during pregnancy if the potential benefit outweighs the potential risks. If you’re pregnant or planning to become pregnant, talk with your doctor about the risks and benefits of using Soliqua 100/33 during pregnancy. It is not known if Soliqua 100/33 passes into breast milk. Before breastfeeding, you should discuss with your doctor the risks and benefits of taking this drug while breastfeeding. Here are answers to some frequently asked questions about Soliqua 100/33.

Yes. Soliqua 100/33 contains two active drugs. One of these is insulin glargine, which is a long-acting insulin.

In clinical trials, Soliqua 100/33 was not found to cause weight gain. In fact, in one clinical study, people who took Soliqua 100/33 for 30 weeks lost about 1.5 pounds. It’s interesting to note that the individual drugs contained in Soliqua 100/33 seem to have differing effects on weight. One of the drugs is insulin glargine, which is a long-acting insulin. Typically, drugs containing insulin have been linked with weight gain. However, the other drug in Soliqua 100/33 is called lixisenatide, which is a glucagon-like peptide 1 (GLP-1) receptor agonist. Medications in the GLP-1 drug class have shown weight loss as a side effect in various clinical studies. If you’re concerned about the effects that Soliqua 100/33 might have on your weight, talk with your doctor.

Soliqua 100/33 and Ozempic are both prescribed to manage blood sugar levels in adults with type 2 diabetes. Since both medications contain a GLP-1 agonist, Soliqua 100/33 and Ozempic can cause similar side effects. Soliqua 100/33 also contains insulin glargine, which can cause some side effects that Ozempic is not likely to cause. The table below details a few shared and different side effects of Soliqua 100/33 compared with those of Ozempic. Talk with your doctor or pharmacist if you’d like to learn more about how these medications compare.

It’s not likely that Soliqua 100/33 will cause weight loss. People taking this drug in clinical trials didn’t report this side effect. Keep in mind that the active ingredients in Soliqua 100/33 have links to both weight gain and weight loss. Soliqua 100/33 contains insulin glargine and lixisenatide. Insulin glargine is a type of long-acting insulin. Weight gain is a common side effect of all types of insulin, including insulin glargine. However, it’s unclear whether weight gain was reported in clinical trials of Soliqua 100/33. Lixisenatide belongs to a group of drugs called glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are known to cause weight loss. Other GLP-1 agonist examples include semaglutide (Ozempic) and dulaglutide (Trulicity). With Soliqua 100/33, you may not experience any changes in your weight since one of its active ingredients (insulin glargine) may cause weight gain, and the other (lixisenatide) may cause weight loss. If you’re concerned about changes in your weight while using Soliqua 100/33, talk with your doctor.

Soliqua 100/33 and Trulicity are both prescribed to manage blood sugar levels in adults with type 2 diabetes. Trulicity contains dulaglutide and belongs to the GLP-1 agonist drug class. Soliqua 100/33 also contains a GLP-1 agonist (lixisenatide). But Soliqua 100/33 also contains insulin glargine, which is a type of insulin. Based on their active ingredients, Soliqua 100/33 and Trulicity may cause similar side effects and different ones as well. The table below compares side effects of Soliqua 100/33 versus Trulicity. If you’d like to learn more about how these medications are alike and different, talk with your pharmacist or doctor.

To help lower your risk of injection site reactions with Soliqua 100/33, it’s important to rotate injection sites each time you administer the drug. You can inject Soliqua 100/33 into your thigh, abdomen, or upper arm. Injection site reactions can happen around the area of skin where you inject the drug. Symptoms include: Soliqua 100/33 may cause lipodystrophy (skin dimpling) or lipohypertrophy (skin thickening) around the injection site. As with all injectable medications, you may have injection site reactions with Soliqua 100/33. But it’s unclear whether these side effects occurred in the drug’s clinical trials. If you’re concerned about injection site reactions, talk with your doctor. They can suggest ways to help relieve this side effect. Learn more about some of the side effects that Soliqua 100/33 may cause.

Some of the side effects from Soliqua 100/33 may be the same as side effects from other types of insulin. For example, low blood sugar is a possible side effect of Soliqua 100/33. And low blood sugar is the most common side effect of all insulin medications. To learn more about this side effect, see the “Side effect specifics” section. Additionally, Soliqua 100/33 may cause weight gain and swelling in the arms or legs. These side effects are common with insulin. Even though they weren’t reported in clinical trials of Soliqua 100/33, they’re still possible. To learn more about the side effects of Soliqua 100/33 compared to other types of insulin, talk with your doctor or pharmacist.

Soliqua 100/33 contains two active ingredients, insulin glargine and lixisenatide. (An active ingredient is what makes a medication work.) Each active ingredient has its own mechanism of action (how it works to treat a condition):

You should inject your daily dose of Soliqua 100/33 within 1 hour before your first meal of the day.

Before using a Soliqua 100/33 pen, you should store it in a refrigerator at a temperature of 36°F to 46°F (2°C to 8°C). After using the pen for the first time, you should store it at a room temperature no higher than 77°F (25°C). Be sure to remove the needle from the pen after giving yourself a dose. Do not store the pen with a needle attached. You should safely dispose of Soliqua 100/33 pens 28 days after opening them, even if they still have medication inside. For information about how to dispose of the drug safely, see this medication safety article. Or ask your doctor about safe ways to dispose of expired medication. If you have additional questions about storing Soliqua 100/33, talk with your doctor or pharmacist.

It’s not likely. In studies of Soliqua 100/33, neither weight gain nor weight loss were reported. It’s important to note that Soliqua 100/33 contains insulin glargine. Weight gain is possible with any insulin product. Soliqua also contains lixisenatide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 receptor agonists may cause weight loss. If you have questions or concerns about your weight and Soliqua 100/33, talk with your doctor or pharmacist. They can suggest ways to maintain a moderate weight.